Lutwick L I, Galgiani J N, Johnson R H, Stevens D A
Am J Med. 1976 Nov;61(5):632-40. doi: 10.1016/0002-9343(76)90141-8.
Four patients with visceral infections due to the fungus Petriellidium boydii, who were recently hospitalized in our institutions, are described. Three of the patients were compromised hosts; in the fourth patient, infection occurred after trauma. All had received prior steroid and antibiotic therapy. Studies of patients with mycetoma or secondary infection of a pulmonary cavity due to this organism and of patients with visceral infections are reviewed. Because of histologic similarities to Aspergillus species, infections due to P. boydii may have been misdiagnosed in the past if the infecting fungus was not isolated in culture. The fungus has been shown to be resistant in vitro to currently available antifungal agents. Resistance to amphotericin and 5-fluorocytosine is demonstrated in our studies. There are few reports of successful chemotherapy of any manifestation of this infection, and no such reports of visceral disease. We demonstrate in vitro sensitivity of isolates in our cases and in others to micronazole, a new antimicrobial agent; this drug may be indicated for treatment of disease due to P. boydii.
本文描述了近期在我们机构住院的4例由博伊德氏霉样真菌引起内脏感染的患者。其中3例患者为免疫功能低下宿主;第4例患者在创伤后发生感染。所有患者均曾接受过类固醇和抗生素治疗。本文回顾了由该病原体引起足菌肿或肺空洞继发感染患者以及内脏感染患者的研究情况。由于在组织学上与曲霉菌属相似,如果感染真菌未在培养中分离出来,过去博伊德氏霉样真菌引起的感染可能被误诊。已证明该真菌在体外对目前可用的抗真菌药物具有耐药性。我们的研究证实了其对两性霉素和5-氟胞嘧啶耐药。关于这种感染任何表现的成功化疗报道很少,内脏疾病尚无此类报道。我们证明了我们病例及其他病例中的分离株对新型抗菌剂咪康唑的体外敏感性;该药物可能适用于治疗博伊德氏霉样真菌引起的疾病。